Blood Biomarker May Help Women Avoid Chemotherapy

Ultrasensitive measures of ovarian reserve could refine treatment decisions for younger women with hormone receptor–positive breast cancer

1

A blood test measuring anti-Müllerian hormone (AMH) may help identify premenopausal women with breast cancer unlikely to benefit from chemotherapy.
2

The analysis of the phase 3 RxPONDER trial established that some postmenopausal women can receive endocrine therapy without chemotherapy.
3

AMH concentrations below 10 pg/mL indicated low ovarian reserve and no measurable benefit from adding chemotherapy to endocrine therapy.
4

Approximately 21 percent of premenopausal participants younger than 55 years had AMH below the 10-pg/mL threshold.
5

The authors called for optimized laboratory methods to measure AMH at low concentrations and further validation in clinical trials.

1